Kovitz Investment Group Partners LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Kovitz Investment Group Partners LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,039 shares of the medical research company's stock after buying an additional 8,875 shares during the period. Kovitz Investment Group Partners LLC's holdings in Thermo Fisher Scientific were worth $27,860,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp lifted its holdings in Thermo Fisher Scientific by 0.8% during the 3rd quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock worth $10,100,655,000 after purchasing an additional 124,996 shares in the last quarter. FMR LLC lifted its holdings in shares of Thermo Fisher Scientific by 19.7% in the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after buying an additional 1,294,453 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.6% in the third quarter. Fisher Asset Management LLC now owns 2,636,558 shares of the medical research company's stock valued at $1,630,896,000 after acquiring an additional 65,586 shares during the period. Ameriprise Financial Inc. increased its holdings in Thermo Fisher Scientific by 32.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock worth $1,372,157,000 after acquiring an additional 604,895 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,443,937 shares of the medical research company's stock valued at $1,511,746,000 after purchasing an additional 61,017 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,150 shares of company stock valued at $25,954,465. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on TMO. Royal Bank of Canada lowered their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Sanford C. Bernstein decreased their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating on the stock in a research report on Thursday, October 24th. Stephens started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 price target for the company. Finally, Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Trading Up 1.6 %

NYSE:TMO traded up $8.50 during midday trading on Friday, reaching $529.36. 1,869,732 shares of the stock traded hands, compared to its average volume of 2,146,533. The stock has a market capitalization of $202.48 billion, a P/E ratio of 33.19, a PEG ratio of 3.56 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $488.02 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a fifty day moving average of $559.78 and a 200 day moving average of $576.07.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the firm earned $5.69 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.